 Print View Attached Docs: |
|||||||||
| 82175:MOTOR AND SENSORY NEUROPATHY EVALUATION | |||||||||
| Alias Names: | Ganglioside / MAG / SGPG / Neuronal (HU) | ||||||||
| Methodology: | Enzyme Immunoassay (EIA) / Capillary Zone Electrophoresis (CZE) / Immunoblot (IB) | ||||||||
| Edit Date: | 5/7/2009 | ||||||||
| Components: | Ganglioside GM1 Autoantibodies / Ganglioside Asialo-GM1 Autoantibodies / Myelin-Associated Glyco (MAG) IgM Autoantibodies / SGPG IgM Autoantibodies / Ganlioside GD1a Autoantibodies / Ganglioside GD1b / Ganglioside GQ1b Autoantibodies / IFE Paraprotein / IFE Interpretation / Neuronal Nuclear (HU) Autoantibodies – WB | ||||||||
| Performed: | Tuesday – Friday | ||||||||
| Released: | 5 days after setup at PeaceHealth Laboratories’ reference lab. | ||||||||
| CPT Code: | 83520-90 x7 / 84181-90 / 86334-90 | ||||||||
| Specimen Collection Details | |||||||||
| Collection: | One 7.5 mL serum separator tube (SST). | ||||||||
| Handling: | Centrifuge and separate serum from cells into a plastic vial. | ||||||||
| Stability: | 7 days ambient, 7 days refrigerated, or 2 months frozen. | ||||||||
| Standard Volume: | 3 mL serum. | ||||||||
| Minimum Volume: | 2.5 mL serum. | ||||||||
| Transport: | Refrigerated. | ||||||||
| Comments: | Low concentrations of one or more autoantibodies in this evaluation can be associated with neurophathies secondary to infectious, inflammatory or systemic autoimmune diseases. However, high concentrations of one or more autoantibodies, especially with paraproteinemia, are suggestive of a primary immune-mediated peripheral neuropathy. | ||||||||
| Rejection Criteria: | Plasma. | ||||||||
| Reference Range: | |||||||||||||||||||
|
Ganglioside GM1 Autoantibodies
|
<25%
|
||||||||||||||||||
|
Ganglioside Asialo-GM1 Autoantibodies
|
<25%
|
||||||||||||||||||
|
Myelin-Assoc Glycoprotein IgM Autoantibodies
|
<1000 Units
|
||||||||||||||||||
|
SGPG IgM Autoantibodies
|
<1.0 EIA Units
|
||||||||||||||||||
|
Ganglioside GD1a Autoantibodies
|
<20%
|
||||||||||||||||||
|
Ganglioside GD1b Autoantibodies
|
<20%
|
||||||||||||||||||
|
Ganglioside GQ1b Autoantibodies
|
<20%
|
||||||||||||||||||